Supporting Information

Figure S1. The dose response curve of compounds 1–3 and cisplatin at each tested cell lines.
Figure S1. Cont.
Figure S1. Cont.

Figure S2. $^1$H-NMR (600 Hz, CDCl$_3$) spectrum of the new compound acerolanin A.
Figure S3. $^{13}$C-NMR (125 MHz, CDCl$_3$) spectrum of the new compound acerolanin A.

Figure S4. The HMBC spectrum of the new compound acerolanin A.
Figure S5. The HSQC spectrum of the new compound acerolanin A.

Figure S6. $^1$H-$^1$H COSY spectrum of the new compound acerolanin A.
Figure S7. $^1$H-NMR (600 MHz, CDCl$_3$) spectrum of the new compound acerolanin B.

Figure S8. $^{13}$C-NMR (125 MHz, CDCl$_3$) spectrum of the new compound acerolanin B.
Figure S9. The HMBC spectrum of the new compound acerolanin B.

Figure S10. The HSQC spectrum of the new compound acerolanin B.
Figure S11. $^1$H-$^1$H COSY spectrum of the new compound acerolanin B.

Figure S12. $^1$H-NMR (600 MHz, CDCl$_3$) spectrum of the new compound acerolanin C.
Figure S13. $^{13}$C-NMR (125 MHz, CDCl$_3$) spectrum of the new compound acerolanin C.

Figure S14. The HMBC spectrum of the new compound acerolanin C.
Figure S15. The HSQC spectrum of the new compound acerolanin C.

Figure S16. $^1$H-$^1$H COSY spectrum of the new compound acerolanin C.